ACCESS Newswire
09 May 2022, 16:43 GMT+10
CAMBRIDGE, MA / ACCESSWIRE / May 9, 2022 / Moderna, Inc. (NASDAQ:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced that that it will host its in-person Science and Technology Day for analysts and investors at 9:00 a.m. ET on Tuesday, May 17 in Boston, MA.
Moderna's Science and Technology Day will feature presentations from Stephen Hoge M.D., President, Melissa Moore Ph.D., Chief Scientific Officer, Scientific Affairs, and Moderna's mRNA and technical development platform scientists with a focus on the Company's newest advances from its commitment to basic and applied sciences.
A live webcast will be available under the 'Events and Presentations' in the Investors section of the Moderna website at investors.modernatx.com. A replay of the webcast will be archived on Moderna's website for one year following the presentation.
About Moderna
In over 10 years since its inception, Moderna has transformed from a research-stage company advancing programs in the field of messenger RNA (mRNA) to an enterprise with a diverse clinical portfolio of vaccines and therapeutics across seven modalities, a broad intellectual property portfolio in areas including mRNA and lipid nanoparticle formulation, and an integrated manufacturing plant that allows for rapid clinical and commercial production at scale. Moderna maintains alliances with a broad range of domestic and overseas government and commercial collaborators, which has allowed for the pursuit of both groundbreaking science and rapid scaling of manufacturing. Most recently, Moderna's capabilities have come together to allow the authorized use and approval of one of the earliest and most effective vaccines against the COVID-19 pandemic.
Moderna's mRNA platform builds on continuous advances in basic and applied mRNA science, delivery technology and manufacturing, and has allowed the development of therapeutics and vaccines for infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases and auto-immune diseases. Moderna has been named a top biopharmaceutical employer by Science for the past seven years. To learn more, visit www.modernatx.com.
Moderna Contact:
Lavina Talukdar
Senior Vice President & Head of Investor Relations
617-209-5834
[email protected]
SOURCE: Moderna, Inc.
Get a daily dose of Detroit Star news through our daily email, its complimentary and keeps you fully up to date with world and business news as well.
Publish news of your business, community or sports group, personnel appointments, major event and more by submitting a news release to Detroit Star.
More InformationEVERGLADES, Florida: Over the weekend, a diverse coalition of environmental activists, Native American leaders, and residents gathered...
BEIJING, China: China's national soccer team may struggle to stir excitement, but its humanoid robots are drawing cheers — and not...
]LONDON, U.K.: A World Health Organization (WHO) expert group investigating the origins of the COVID-19 pandemic released its final...
DOVER, Delaware: California Governor Gavin Newsom has taken legal aim at Fox News, accusing the network of deliberately distorting...
FRANKFURT, Germany: Germany has become the latest country to challenge Chinese AI firm DeepSeek over its data practices, as pressure...
TORONTO, Canada: Harvard University and the University of Toronto have created a backup plan to ensure Harvard graduate students continue...
In his second term, President Donald Trump has not taken many actions that draw near-universal praise from across the political spectrum....
Detroit,[US], June 29 (ANI): Three birdies on the back nine helped Akshay Bhatia make the cut on the line at the Rocket Classic on...
The Democratic Republic of the Congo (DRC) and Rwanda signed a historic peace agreement in Washington on Friday to end years of armed...
The European Commission president has been under scrutiny over a multi-billion-dollar Covid-19 vaccine deal A group of lawmakers...
The European Commission president has been under scrutiny over a multi-billion-dollar Covid-19 vaccine deal A group of lawmakers...
New Delhi [India], June 26 (ANI): Amardeep Singh Bhatia, Secretary of the Department for Promotion of Industry and Internal Trade (DPIIT),...